Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure | Circulation
Pulmonary Arterial Hypertension: Current Therapeutic Strategies
Chin KM et al. (2005) The right ventricle in pulmonary hypertension. Coron Artery Dis 16: 13–18
Fishman AP (2004) Primary pulmonary arterial hypertension: a look back. J Am Coll Cardiol 43 (Suppl S): S2–S4
Galie N et al.; Task Force (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25: 2243–2278
D'Alonzo GE et al. (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115: 343–349
Simonneau G et al. (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (Suppl S): S5–S12
Loyd JE et al. (1988) Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 138: 952–957
Machado RD et al. (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68: 92–102
Thomson J et al. (2001) Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor [Abstract]. J Heart Lung Transplant 20: a149
Bobik A (2006) Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26: 1712–1720
Machado RD et al. (2006) Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27: 121–132
Elliott CG et al. (2006) Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113: 2509–2515
Christman BW et al. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70–75
Giaid A and Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221
Giaid A et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739
Humbert M et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (Suppl S): S13–S24
Galie N et al. (2004) Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 (Suppl S): S81–S88
Olschewski H et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322–329
Seyfarth HJ et al. (online 11 May 2006) Long-term bosentan in chronic thromboembolic pulmonary hypertension [http://content.Karger.Com/ProdukteDB/produkte.Asp?Aktion=ShowAbstract&ArtikelNr=93322&Ausgabe=0&ProduktNr=224278] (accessed 19 March 2007)
Ahmadi-Simab K et al. (2006) Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 36 (Suppl 3): S44–S48
Madden BP et al. (2006) A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44: 372–376
Barst RJ (1986) Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 89: 497–503
Pepke-Zaba J et al. (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338: 1173–1174
Rubin LJ et al. (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66: 334–338
Morgan JM et al. (1991) Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 84: 1145–1149
Sitbon O et al. (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105–3111
Rich S et al. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81
Woodmansey PA et al. (1996) Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 75: 171–173
Franz IW et al. (2002) The effect of amlodipine on exercise-induced pulmonary hypertension and right heart function in patients with chronic obstructive pulmonary disease. Z Kardiol 91: 833–839
Fuster V et al. (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580–587
Robbins IM et al. (2006) A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 27: 578–584
Veyssier-Belot C et al. (1999) Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 44: 274–282
Barst RJ et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296–302
McLaughlin VV et al. (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477–1482
Sitbon O et al. (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780–788
Simonneau G et al.; Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165: 800–804
McLaughlin VV et al.; Treprostinil Study Group (2003) Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41: 293–299
Gomberg-Maitland M et al. (2005) Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172: 1586–1589
Tapson VF et al. (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129: 683–688
Hoeper MM et al. (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group. J Am Coll Cardiol 35: 176–182
Hoeper MM et al. (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–1870
Nagaya N et al. (1999) Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34: 1188–1192
Galie N et al.; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39: 1496–1502
Barst RJ et al.; Beraprost Study Group (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41: 2119–2125
Cacoub P et al. (1993) Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 71: 448–450
Kedzierski RM et al. (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851–876
Rubin LJ et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903
Galie N et al. (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61: 227–237
Galie N et al. (2003) Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41: 1380–1386
Channick R et al. (2001) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 20: 262–263
Barst RJ et al. (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169: 441–447
Barst RJ et al. (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47: 2049–2056
Billman GE (2002) Ambrisentan (Myogen). Curr Opin Investig Drugs 3: 1483–1486
Galie N et al. (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46: 529–535
Tantini B et al. (2005) Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100: 131–138
Prasad S et al. (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343: 1342
Bhatia S et al. (2003) Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78: 1207–1213
Michelakis ED et al. (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108: 2066–2069
Sastry BK et al. (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43: 1149–1153
Galie N et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157
Affuso F et al. (2006) Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 108: 429–431
Nagaoka T et al. (2006) Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 100: 996–1002
Abe K et al. (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385–393
Ishikura K et al. (2006) Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174–178
Guilluy C et al. (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146: 1010–1018
Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115: 2691–2694
Dingli D et al. (2001) Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 120: 801–808
Hoffman R et al. (2006) Is bone marrow fibrosis the real problem? Blood 107: 3421–3422
Schermuly RT et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811–2821
Ghofrani HA et al. (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412–1413
Souza R et al. (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61: 736
Patterson KC et al. (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145: 152–153
Kerkela R et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908–916
Hu H et al. (2006) Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun 339: 59–64
Taraseviciene-Stewart L et al. (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291: L668–L676
Kao PN (2005) Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127: 1446–1452
Henriques-Coelho T et al. (2006) Ghrelin reverses molecular, structural and hemodynamic alterations of the right ventricle in pulmonary hypertension. Rev Port Cardiol 25: 55–63
Taraseviciene-Stewart L et al. (2005) Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26: 1292–300
Marcos E et al. (2004) Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94: 1263–1270
Cogolludo A et al. (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and Kv1.5 channel internalization. Circ Res 98: 931–938
Guignabert C et al. (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812–2819
Petkov V et al. (2006) The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation. Ann NY Acad Sci 1070: 481–483
Petkov V et al. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339–1346
Michelakis ED et al. (2003) The NO− K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. Adv Exp Med Biol 543: 293–322
Maurey C et al. (2006) Interaction of KATP channels and endothelin-1 in lambs with persistent pulmonary hypertension of the newborn. Pediatr Res 60: 252–257
Pozeg ZI et al. (2003) In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107: 2037–2044
McMurtry MS et al. (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95: 830–840
Wong PS et al. (2001) Primary pulmonary hypertension in pregnancy. JR Soc Med 94: 523–525
Rich S et al. (1998) The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114: 787–792
Naeije R and Vachiery JL (2001) Medical therapy of pulmonary hypertension: conventional therapies. Clin Chest Med 22: 517–527
Radley-Smith R et al. (2006) Transplantation as a treatment for end-stage pulmonary hypertension in childhood. Paediatr Respir Rev 7: 117–122
Habashi JP et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117–121
Nakamoto T et al. (2005) Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. Eur J Pharmacol 528: 43–51
Humbert M et al. (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24: 353–359
Hoeper MM et al. (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28: 691–694
Seyfarth HJ et al. (2005) Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 128: 709–713
McLaughlin VV et al. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257–1263
Gomberg-Maitland M (2006) Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Eur Respir J 28: 683–686
Wilkens H et al. (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218–1222
Gomberg-Maitland M et al. (2005) Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 96: 1334–1336
Clozel M et al. (2006) Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231: 967–973
Hoeper MM et al. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24: 1007–1010
Morice AH et al. (2005) Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension. Eur Respir J 26: 180
How Pulmonary Hypertension Guidelines Improve Patient Care
What is Pulmonary Hypertension and Why Were Guidelines Needed?Pulmonary hypertension means the walls of the lung arteries have become stiff, damaged and narrow. Blood flow becomes more difficult leading to rising blood pressure in the lungs and the right side of the heart must work harder to pump oxygenated blood throughout the body. This added stress to the heart can lead to heart failure. In most cases, pulmonary hypertension cannot be cured, but proper treatment can improve symptoms and slow the disease's progression.
Oftentimes patients living with pulmonary hypertension were diagnosed long after their symptoms began due to a similarity of symptoms to more common lung diseases like asthma and COPD. The most common symptoms of PH include shortness of breath, fatigue, chest pain, dizziness and fainting, heart palpitations and edema.
What is it Like Living with Pulmonary Hypertension?Lindsay was 23 years old when diagnosed with pulmonary arterial hypertension (PAH) and shared her story of learning how to read and listen to her body so she could best advocate for her care. PAH is classified by the World Health Organization (WHO) as Group 1 and occurs when the arteries in your lung become thickened and narrow, which blocks blood flow resulting in increased blood pressure in the lungs that puts stress on the right side of the heart. Lindsay is a huge proponent of self-advocating for open and ongoing communication with a specialist, seeking support from others living with the disease and following medication treatments exactly as prescribed.
Delores was diagnosed with another type of pulmonary hypertension, chronic thromboembolic pulmonary hypertension (CTEPH). This form of pulmonary hypertension is classified by the WHO as Group 4 and occurs when blood vessels in the lung have been blocked by a clot for an extended period. Delores shared her experience of going back and forth between lung and heart doctors to figure out what was going on due to her symptoms being like many other cardiopulmonary diseases. Finally, a specialist was able to determine that both her lungs were filled with blood clots and treatment began to ease her symptoms and stop the disease from progressing. Delores wants more people to know about CTEPH, "Even doctors might think you have something else because the symptoms are similar to other health issues. Because CTEPH is a rare disease, many people don't know about it."
What Resources are Available for Patients Living with Pulmonary Hypertension?If you have been newly diagnosed with pulmonary hypertension, no matter what type it may be, learn all you can about the disease, treatment options, support groups and how to manage your PH. Your healthcare provider can help you understand your disease and refer you to a specialist or other resources. They can explain if your treatment follows guidelines-based care, and if it differs, why that makes sense in your situation. If the cost of treatment is a burden for you and your family, speak with your healthcare provider about your concerns and available options.
You can also contact the Lung HelpLine at 1-800-LUNGUSA to speak with medical professionals who can help guide you to available resources.
Learn more at Lung.Org.
Support for this program was provided in part by Merck
Fewer Vitamin D Receptors In PAH Lungs, Blood Vessel Cells: Study
Lung tissue and cells from the blood vessels that pass through the lungs derived from people with pulmonary arterial hypertension (PAH) produced fewer vitamin D receptors (VDRs) than normal, a study shows.
Treating PAH patient-derived blood vessel cells with calcitriol, the active form of vitamin D, reduced VDR deficiency and suppressed the excessive growth of these cells, a hallmark feature of PAH.
"These data reinforce the view that [vitamin D] deficiency may contribute to the [development] of PAH," the study's scientists wrote in "Vitamin D receptor and its antiproliferative effect in human pulmonary arterial hypertension," which was published in Scientific Reports.
In PAH, high blood pressure is caused by the narrowing of the pulmonary arteries, the blood vessels that carry deoxygenated blood from the heart to the lungs to be oxygenated. Arterial narrowing is triggered by the excessive growth of smooth muscle cells (PASMC), the most common cells in blood vessel walls, and endothelial cells (PAEC), which line the inside of blood vessels.
With reduced blood flow through the lungs, PAH symptoms arise due to a lack of oxygen in the blood and include shortness of breath, fatigue, chest pain, dizziness, and fainting. Because high blood pressure in these arteries makes the heart work harder to pump blood, PAH can lead to heart failure.
PAH patients are deficient in vitamin D compared with the general population or people with other cardiovascular diseases, studies show. Such a deficiency has been linked with poor outcomes, including higher pulmonary artery blood pressure, decreased exercise tolerance, and reduced survival.
Calcitriol interacts with the vitamin D receptor, a protein produced in many cell types, including PASMCs and PAECs. When calcitriol binds to VDRs, it enters the nucleus and activates several genes. Along with its well-known function in metabolizing calcium and phosphorus, calcitriol/VDRs also influence cell growth and migration, blood vessel health, and immune responses.
Studyinig VDR production in PAH patientsHere, a research team led by scientists at the Complutense University of Madrid examined the expression, or production, profile of VDR in human lung tissue, PASMCs, and PAECs derived from PAH patients and healthy people to explore the role of VDRs in the pulmonary arteries and PAH.
In human lung tissue, the activity of the gene that encodes VDRs was reduced, as were the levels of VDR protein, in PAH patients compared with healthy people. VDR expression was also reduced in PASMCs from PAH patients, but not in PAECs versus healthy people.
Low levels of lung VDRs are associated with several other lung diseases, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, and correlate with worse outcomes.
When treated with calcitriol for 48 hours, VDR expression was significantly increased in PASMCs of PAH patients to levels that were similar to healthy people.
A closer look found that calcitriol suppressed the growth of PASMCs from healthy people and PAH patients in a dose-dependent manner. This effect was more prominent in PAH cells at higher calcitriol doses than healthy people, however.
Using control PASMCs, calcitriol boosted the expression of the KCNK3 gene, which encodes for a potassium channel protein involved in pulmonary circulation, but decreased the expression of BIRC5, a gene that encodes survivin, a protein that blocks programmed cell death. Calcitriol also significantly enhanced the expression of BMP4, which codes for a protein involved in cell growth and migration. The researchers confirmed that calcitriol suppressed PASMC growth partly by modulating the BMP and survivin signaling pathways. Still, calcitriol had no anti-growth effect in PAECs, nor did it act as a vasodilator, a medicine that widens blood vessels.
"PAH patients not only present severe deficit of [vitamin D], but also a reduction in lung VDR," the scientists wrote. "Calcitriol rescues VDR expression and induces an antiproliferative effect in PASMC."
Comments
Post a Comment